PT  - JOURNAL ARTICLE
ED  - Vidt, Donald G.
ED  - Bakst, Alan
AU  - Falk, Gary W.
TI  - Omeprazole: a new drug for the treatment of acid^peptic diseases
DP  - 1991 Sep 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 418--427
VI  - 58
IP  - 5
4099  - http://www.ccjm.org/content/58/5/418.short
4100  - http://www.ccjm.org/content/58/5/418.full
SO  - Cleve Clin J Med1991 Sep 01; 58
AB  - Omeprazole is the first of a new class of gastric antisecretory drugs, proton pump inhibitors. It inhibits the H+,K+-adenosinetriphosphatase enzyme of the gastric parietal cell, resulting in potent, long-lasting suppression of basal and stimulated acid secretion. The drug is currently approved for treatment of gastroesophageal reflux disease and Zollinger-Ellison syndrome. In clinical trials, treatment with omeprazole results in rapid healing of duodenal ulcers; it is also effective in treating gastric ulcer disease. It is uniformly well tolerated without significant adverse effects, although animal studies linked profound long-term suppression of gastric acid secretion with the development of gastric carcinoids. Potential future uses include the prophylaxis of ulceration secondary to stress or use of nonsteroidal anti-inflammatory drugs, and the prophylaxis of recurrent peptic ulcer disease.